OncoMatch/Clinical Trials/NCT07644559
A Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Pancreatic Cancer
Official title: A Phase 2, Open-label Study of VS-7375, an Oral KRAS G12D (ON/OFF) Inhibitor, as Monotherapy and With Cetuximab, in Patients With Metastatic KRAS G12D-Mutated Pancreatic Cancer (TARGET-D 201)
Is NCT07644559 recruiting? Yes, currently enrolling (Oct 2026). This Phase 2 trial studies multiple treatments including VS-7375 and cetuximab (or panitumumab if α-gal IgE+ or cetuximab reaction) for pancreatic ductal adenocarcinoma (pdac).
Treatment: VS-7375 · cetuximab (or panitumumab if α-gal IgE+ or cetuximab reaction) — This study will assess the safety and efficacy of VS-7375 alone and in combination with cetuximab in patients with metastatic KRAS G12D - mutated Pancreatic Cancer
Check if I qualifyExtracted eligibility criteria
Treatments studied
Targeted therapy
Other
Cancer type
Pancreatic Cancer
Biomarker criteria
Required: KRAS g12d
Local testing confirmed KRAS G12D mutation (tissue required for confirmatory central testing)
Excluded: KRAS co-existing pathogenic or likely pathogenic ras mutation(s)
Have any documented co-existing pathogenic or likely pathogenic RAS mutation(s) in KRAS
Disease stage
Metastatic disease required
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Cannot have received: direct RAS inhibitor
Receipt of prior direct RAS inhibitor
Lab requirements
Blood counts
Kidney function
Liver function
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- START- Los Angeles · Los Angeles, California
- Cedars-Sinai Medical Center · Los Angeles, California
- Valkyrie Clinical Trials · Los Angeles, California
- Mayo Clinical Florida · Jacksonville, Florida
- Moffitt Cancer Center · Tampa, Florida
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT07644559 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior direct RAS inhibitor disqualifies patients from enrollment.
Does this trial require KRAS?
Yes, KRAS g12d is a required biomarker for enrollment.
Are patients with KRAS alterations eligible?
No. KRAS co-existing pathogenic or likely pathogenic ras mutation(s) is an exclusion criterion.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages